Estenda Solutions Inc, Wayne, Pennsylvania.
Phoenix Indian Medical Center, Phoenix, Arizona.
JAMA Ophthalmol. 2023 Apr 1;141(4):366-375. doi: 10.1001/jamaophthalmol.2023.0167.
Estimates of diabetic retinopathy (DR) incidence and progression in American Indian and Alaska Native individuals are based on data from before 1992 and may not be informative for strategizing resources and practice patterns.
To examine incidence and progression of DR in American Indian and Alaska Native individuals.
DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from January 1, 2015, to December 31, 2019, and included adults with diabetes and no evidence of DR or mild nonproliferative DR (NPDR) in 2015 who were reexamined at least 1 time during the 2016 to 2019 period. The study setting was the Indian Health Service (IHS) teleophthalmology program for diabetic eye disease.
Development of new DR or worsening of mild NPDR in American Indian and Alaska Native individuals with diabetes.
Outcomes were any increase in DR, 2 or more (2+) step increases, and overall change in DR severity. Patients were evaluated with nonmydriatic ultra-widefield imaging (UWFI) or nonmydriatic fundus photography (NMFP). Standard risk factors were included.
The total cohort of 8374 individuals had a mean (SD) age of 53.2 (12.2) years and a mean (SD) hemoglobin A1c level of 8.3% (2.2%) in 2015, and 4775 were female (57.0%). Of patients with no DR in 2015, 18.0% (1280 of 7097) had mild NPDR or worse in 2016 to 2019, and 0.1% (10 of 7097) had PDR. The incidence rate from no DR to any DR was 69.6 cases per 1000 person-years at risk. A total of 6.2% of participants (441 of 7097) progressed from no DR to moderate NPDR or worse (ie, 2+ step increase; 24.0 cases per 1000 person-years at risk). Of patients with mild NPDR in 2015, 27.2% (347 of 1277) progressed to moderate NPDR or worse in 2016 to 2019, and 2.3% (30 of 1277) progressed to severe NPDR or worse (ie, 2+ step progression). Incidence and progression were associated with expected risk factors and evaluation with UWFI.
In this cohort study, the estimates of DR incidence and progression were lower than those previously reported for American Indian and Alaska Native individuals. The results suggest extending the time between DR re-evaluations for certain patients in this population, if follow-up compliance and visual acuity outcomes are not jeopardized.
美国印第安人和阿拉斯加原住民的糖尿病视网膜病变 (DR) 发病率和进展的估计是基于 1992 年之前的数据,因此可能无法为资源规划和实践模式提供信息。
检查美国印第安人和阿拉斯加原住民的 DR 发病率和进展情况。
设计、设置和参与者:这是一项回顾性队列研究,于 2015 年 1 月 1 日至 2019 年 12 月 31 日进行,纳入了 2015 年无 DR 或轻度非增殖性 DR(NPDR)证据且在 2016 年至 2019 年期间至少接受过 1 次复查的糖尿病患者。研究地点是印第安人健康服务部(IHS)的糖尿病眼病 teleophthalmology 项目。
美国印第安人和阿拉斯加原住民糖尿病患者新出现 DR 或轻度 NPDR 恶化。
结果是任何 DR 的增加、2 个或更多(2+)步增加以及 DR 严重程度的总体变化。患者接受非散瞳超广角成像(UWFI)或非散瞳眼底摄影(NMFP)评估。纳入了标准风险因素。
总共有 8374 名患者的平均(SD)年龄为 53.2(12.2)岁,2015 年平均(SD)糖化血红蛋白水平为 8.3%(2.2%),其中 4775 名为女性(57.0%)。在 2015 年没有 DR 的患者中,18.0%(1280/7097)在 2016 年至 2019 年期间出现轻度 NPDR 或更严重的情况,0.1%(10/7097)出现 PDR。从无 DR 到任何 DR 的发病率为每 1000 人年 69.6 例。共有 6.2%的参与者(441/7097)从无 DR 进展为中度 NPDR 或更严重的情况(即 2+ 步进展;每 1000 人年风险率为 24.0 例)。在 2015 年有轻度 NPDR 的患者中,27.2%(347/1277)在 2016 年至 2019 年期间进展为中度 NPDR 或更严重的情况,2.3%(30/1277)进展为严重 NPDR 或更严重的情况(即 2+ 步进展)。发病率和进展与预期的风险因素相关,并与 UWFI 评估相关。
在这项队列研究中,DR 发病率和进展的估计值低于之前报道的美国印第安人和阿拉斯加原住民的数据。结果表明,如果不影响随访依从性和视力结果,可以延长该人群中某些患者的 DR 重新评估时间。